Tatiane E Hirose1, Eliane M C P Maluf2, Cristina O Rodrigues3. 1. Department of Pediatrics, Health Sciences Section, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brazil. Electronic address: tatiane_hirose@hotmail.com. 2. Department of Internal Medicine, Health Sciences Section, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brazil; Discipline of Family Health, Maternal-Child Section, Universidade Positivo, Curitiba, PR, Brazil. 3. Department of Pediatrics, Health Sciences Section, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brazil.
Abstract
OBJECTIVES: To evaluate the possible effects of the introduction of the pneumococcal conjugate 10-valent vaccine schedule in the state of Parana on pneumococcal meningitis cases and to assess the distribution of serotypes among cases. METHOD: Cross-sectional study with retrospective data collection of cases of pneumococcal meningitis in the state of Paraná reported to Sistema de Informação de Agravos de Notificação (SINAN), from 1998 to 2011. A total of 1,339 cases of pneumococcal meningitis were analyzed; 1,205 cases from the pre-vaccine period (1998-2009) were compared to 134 cases from the post-vaccine period (2010-2011). Descriptive and comparative statistical analyses (chi-squared test and prevalence ratio) were performed using JMP 5.1.2 statistical software (JMP Statistical Discovery, North Carolina, USA) and EPI INFO 6 (Centers for Disease Control and Prevention, Georgia, EUA). RESULTS: There was a significant reduction in the mean rates of incidence and mortality in the general population. The analysis of cases in the pre- and post-vaccination periods in the age groups covered by vaccination (younger than 2 years) showed significant reductions in incidence rates (6.01 cases/100,000 to 2.49 cases/100,000 individuals) and mortality (1.85 cases/100,000 population to 0.47 cases/100,000 population), while the mean lethality rate did not change significantly. There was a significant reduction in cases whose serotypes are included in the vaccine (80.7% to 53.3%). CONCLUSION: Even after a short time of use, the 10-valent pneumococcal conjugate vaccine has already had a significant impact in reducing the incidence and mortality of meningitis cases among infants, as well as the reduction of cases whose serotypes are included in the vaccine.
OBJECTIVES: To evaluate the possible effects of the introduction of the pneumococcal conjugate 10-valent vaccine schedule in the state of Parana on pneumococcal meningitis cases and to assess the distribution of serotypes among cases. METHOD: Cross-sectional study with retrospective data collection of cases of pneumococcal meningitis in the state of Paraná reported to Sistema de Informação de Agravos de Notificação (SINAN), from 1998 to 2011. A total of 1,339 cases of pneumococcal meningitis were analyzed; 1,205 cases from the pre-vaccine period (1998-2009) were compared to 134 cases from the post-vaccine period (2010-2011). Descriptive and comparative statistical analyses (chi-squared test and prevalence ratio) were performed using JMP 5.1.2 statistical software (JMP Statistical Discovery, North Carolina, USA) and EPI INFO 6 (Centers for Disease Control and Prevention, Georgia, EUA). RESULTS: There was a significant reduction in the mean rates of incidence and mortality in the general population. The analysis of cases in the pre- and post-vaccination periods in the age groups covered by vaccination (younger than 2 years) showed significant reductions in incidence rates (6.01 cases/100,000 to 2.49 cases/100,000 individuals) and mortality (1.85 cases/100,000 population to 0.47 cases/100,000 population), while the mean lethality rate did not change significantly. There was a significant reduction in cases whose serotypes are included in the vaccine (80.7% to 53.3%). CONCLUSION: Even after a short time of use, the 10-valent pneumococcal conjugate vaccine has already had a significant impact in reducing the incidence and mortality of meningitis cases among infants, as well as the reduction of cases whose serotypes are included in the vaccine.
Authors: Sandra Rodrigues da Silva; Luane Marques de Mello; Anderson Soares da Silva; Altacílio Aparecido Nunes Journal: Rev Paul Pediatr Date: 2016-03-30
Authors: Godwin Oligbu; Sarah Collins; Abdelmajid Djennad; Carmen L Sheppard; Norman K Fry; Nick J Andrews; Ray Borrow; Mary E Ramsay; Shamez N Ladhani Journal: Emerg Infect Dis Date: 2019-09 Impact factor: 6.883
Authors: Viviana de Egea; Patricia Muñoz; Maricela Valerio; Arístides de Alarcón; José Antonio Lepe; José M Miró; Juan Gálvez-Acebal; Pablo García-Pavía; Enrique Navas; Miguel Angel Goenaga; María Carmen Fariñas; Elisa García Vázquez; Mercedes Marín; Emilio Bouza Journal: Medicine (Baltimore) Date: 2015-09 Impact factor: 1.817
Authors: Lucia Helena de Oliveira; Luiz Antonio B Camacho; Evandro S F Coutinho; Martha S Martinez-Silveira; Ana Flavia Carvalho; Cuauhtemoc Ruiz-Matus; Cristiana M Toscano Journal: PLoS One Date: 2016-12-12 Impact factor: 3.240